$13.13
4.48% day before yesterday
Nasdaq, Dec 27, 09:46 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$13.04
-12.08 48.09% 1M
-11.76 47.42% 6M
-8.38 39.12% YTD
-8.82 40.35% 1Y
-23.46 64.27% 3Y
-3.72 22.20% 5Y
-3.96 23.29% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.70 5.09%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Market capitalization $396.79m
Enterprise Value $333.73m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.84
P/S ratio (TTM) P/S ratio 6.94
P/B ratio (TTM) P/B ratio 4.70
Revenue growth (TTM) Revenue growth 282.17%
Revenue (TTM) Revenue $57.17m
EBIT (operating result TTM) EBIT $-140.08m
Free Cash Flow (TTM) Free Cash Flow $-103.43m
Cash position $430.12m
EPS (TTM) EPS $-6.07
P/E forward negative
P/S forward 7.10
EV/Sales forward 5.97
Short interest 31.86%
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a AnaptysBio, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
73%
Hold
27%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
57 57
282% 282%
100%
- Direct Costs 2.40 2.40
1% 1%
4%
55 55
335% 335%
96%
- Selling and Administrative Expenses 38 38
2% 2%
67%
- Research and Development Expense 154 154
27% 27%
270%
-138 -138
6% 6%
-241%
- Depreciation and Amortization 2.40 2.40
1% 1%
4%
EBIT (Operating Income) EBIT -140 -140
6% 6%
-245%
Net Profit -166 -166
12% 12%
-290%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Negative
Reuters
18 days ago
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
Negative
Reuters
18 days ago
AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.
Neutral
GlobeNewsWire
18 days ago
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe at...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 117
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today